Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia
- 1 October 2006
- journal article
- Published by American Society of Hematology in Blood
- Vol. 108 (7) , 2435-2437
- https://doi.org/10.1182/blood-2006-04-018259
Abstract
An acquired V617F JAK2 mutation occurs in patients with polycythemia vera (PV) or essential thrombocythemia (ET). In a proportion of V617F-positive patients, mitotic recombination produces mutation-homozygous cells that come to predominate with time. However, the prevalence of homozygosity is unclear, as previous reports studied mixed populations of wild-type, V617F-heterozygous, and V617F-homozygous mutant cells. We therefore analyzed 1766 individual hematopoietic colonies from 34 patients with PV or ET in whom granulocyte sequencing demonstrated that the mutant peak did not predominate. V617F-positive erythroid burst-forming units (BFU-Es) were more frequent in patients with PV compared with patients with ET (P = .022) and, strikingly, V617F-homozygous BFU-Es were detected in all 17 patients with PV, but in none of the patients with ET (P < .001). Moreover, mutation-homozygous cells were present in 2 patients with ET after polycythemic transformation. These results demonstrate that V617F-homozygous erythroid progenitors are present in most patients with PV but occur rarely in those with ET.Keywords
This publication has 15 references indexed in Scilit:
- Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective studyThe Lancet, 2005
- TheJAK2V617Ftyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlatesBritish Journal of Haematology, 2005
- Concomitant neutrophil JAK2V617F mutation screening and PRV‐1 expression analysis in myeloproliferative disorders and secondary polycythaemiaBritish Journal of Haematology, 2005
- Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2V617F in granulocytesBritish Journal of Haematology, 2005
- Identification of an Acquired JAK2 Mutation in Polycythemia VeraJournal of Biological Chemistry, 2005
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisPublished by Elsevier ,2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersThe Lancet, 2005
- Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia veraExperimental Hematology, 2002